Commit To Buy Eli Lilly At $750, Earn 8.3% Using Options

A options-focused note on Eli Lilly (LLY) evaluates selling the Jan 2028 $750 put: at the current share price of $1,033.37 the trade yields a 4.2% annualized return (premium implied $62.20) and would result in a $687.80 cost basis if exercised. The position only captures upside via the premium unless shares fall ~28.1% to the strike; by comparison LLY’s trailing dividend yield is 0.7%. The piece highlights a trailing-12-month volatility of 40% (251 trading days + current price) as a volatility and risk guide for judging whether the premium compensates downside risk.

Analysis

Market structure: The LLY cash-secured Jan 2028 $750 put trade (current price $1,033.37; strike 28% below spot) highlights demand for yield via options versus owning growth equity — sellers capture ~4.2% annualized premium vs LLY's 0.7% dividend, but only if comfortable owning LLY at an effective cost basis of $687.80 (~33% below today). This favors income-seeking, yield-chasing allocators over long-equity holders and slightly increases downside liquidity supply if large put books are assigned in a stress move.

Risk assessment: Key tails are idiosyncratic (regulatory setbacks, trial failures, pricing/regulatory risk) that could easily exceed the 40% trailing vol used — a single clinical or pricing shock could move LLY >30% and trigger assignment. Near-term (days–months) risks: IV spikes around trial/earnings; medium-term (6–18 months): patent/market-share shifts; long-term: durable demand for LLY franchises and margin resilience.

Trade implications: Mechanically, selling Jan 2028 $750 cash-secured puts is attractive only if you truly want to own LLY at $687.80; if not, prefer short-dated put-selling (30–90d) to harvest theta and re-evaluate post-catalysts. For hedged equity exposure, use 12–18 month bull-call spreads (e.g., buy 2026/2027 900/1200 call spreads) or buy deep ITM shares with 6–12 month protective puts when IV < realized vol.

Contrarian angles: Consensus understates skew risk — implied premium may look small vs dividend but understates binary downside. If IV compresses below 35% while fundamentals stay intact, selling premium is likely profitable; conversely, if IV >50% around a negative catalyst, buying protection or long volatility via calendar/backspread pays. Historical parallel: biotech one-off shocks produce >40% moves, so price thresholds matter more than nominal yield.

Key Decisions for Investors

• Establish a 1–2% portfolio position by selling cash-secured Jan 2028 LLY $750 puts only if comfortable buying at $687.80; cap allocation because assignment implies ~33% drawdown from current levels; close if LLY >900 or IV increases +10 vol points.
• If you want equity upside with limited assignment risk, buy a 12–18 month LLY 900/1200 call spread sized 0.5–1% portfolio — max loss equals premium, target 2–3x return if LLY >1200 within expiry.
• Short 30–90 day OTM puts (e.g., 60–120 days) tactically to harvest theta but rotate exposure before major biotech/regulatory catalysts; reduce or stop new short-put issuance if IV rises >50% or realized vol exceeds 45%.
• Pair trade for relative value: go long LLY equity (1–2%) and short PFE (1–1.5%) to express growth over legacy pharma; tighten if LLY underperforms by >10% relative to PFE over 30 days or ahead of major readouts.
• Monitor four triggers in next 90–180 days: (1) FDA/trial readouts and earnings dates (close or hedge positions 7–14 days prior), (2) IV vs realized vol spread (prefer selling when IV ≥ realized +5–10 pts), (3) large insider or institution buying/selling, (4) LLY price crossing $900 and $750 — use these as automatic re-assessment/stop levels.